• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Cannabis

The New Small Biotechs Heating Up the Medical Cannabis Space

These companies are working to plant their flag in a new landscape.
By DEBRA BORCHARDT
Jan 25, 2019 | 11:00 AM EST
Stocks quotes in this article: RSCZF, JNJ, AZN

Pharmaceutical companies have no desire to be left behind as medical cannabis gets legalized in more states. The likelihood of even adult-use cannabis getting legalized is looking pretty solid, too. That has these companies working to see where they can plant their flag in the new landscape.

ReFormation Pharmaceuticals

ReFormation Pharmaceuticals is led by scientist, founder, CEO and chief science officer, Professor Jagdeep Nanchahal, of the University of Oxford. ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury. The scientists combine this molecule and a synthetic non-psychoactive cannabinoid, which they are developing into a first-in-class therapy.

Resinco Capital Partners (RSCZF) (CSE: RIN) just fully acquired ReFormation Pharmaceuticals.

"Many pharma companies had programs in cannabis receptors, but did not pursue their efforts until now. They have deep pockets and good starting points, saving themselves several years of research. Companies like ReFormation Pharmaceuticals, a second generation medical marijuana company, has the upper hand against new pharmaceuticals that will take an average of 10 years to develop a drug," said Alex Somjen, Resinco CEO.

Resinco Capital Partners is an investment company specializing in providing early-stage financing to private and public companies as well as medical cannabis pharmaceutical companies. It engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early-stage investment opportunities that adequately reflect the risk profile.

Somjen added, "The Global Stem Cells Market is estimated to grow to $9.03 Billion by 2023 and having a company that focuses on an innovative approach to repair vital organs will be a beneficial investment as we position ourselves as a global investment company with an emphasis in 'Second generation' medicinal marijuana companies."

CannBioRex Pharmaceuticals

CannBioRex Pharmaceuticals Corp. is a medical cannabis company based in Toronto, but its research and development is being conducted in the U.K. and Israel. Prof Sir Marc Feldmann and Prof Raphael Mechoulam worked together for 20 years before founding CannBioRex. Feldman is the CEO and co-founder of the company.

CannBioRex uses synthetic pharmaceutical-grade cannabinoids to treat arthritis, pain (acute and chronic), diabetes and obesity. Feldman is credited with the discovery and commercialization of the anti-TNF drug used for rheumatoid arthritis that has generated sales of $36 billion in the U.S.

"Professor Raphi Mechoulam and I formed CannBioRex in 2018 specifically for the purpose of developing synthetic compounds related to non-psychoactive moieties of cannabis into FDA-regulated pharmaceutical treatments for a number of unmet needs. This is the second generation of the medical cannabis industry, which intends to develop cannabis treatments through rigorous clinical trials using FDA approved practices, where the medical benefits are based on hard science and government regulation," said Feldmann.

In October 2018, CannBioRex filed a preliminary prospectus for an initial public offering (IPO) for gross proceeds of $7 million through the issuance of common shares to be priced. The company applied to list its common shares on the Canadian Securities Exchange (CSE). Canaccord Genuity Corp. acts as sole underwriter for the offering. CannBioRex has raised over $4.3 million in equity financing since its inception in March 2018. Its last financing was priced at $0.10 per share.

Katexco Pharmaceuticals

Katexco Pharmaceuticals is another medical marijuana pharmaceutical company that is developing innovative, orally available therapies using endocannabinoid and nicotine receptors to treat inflammatory diseases. At this time, the company is private, but worth keeping an eye on. The company was created by Stanford University scientific pioneers and collaborators, Dr. Jonathan Rothbard and Professor Lawrence Steinman.

Rothbard is CEO, Chief Scientific Officer and Co-Founder of Katexco. His track record includes founding Amylin Pharmaceuticals, which AstraZeneca (AZN) acquired in 2012.

This company is focused on treating inflammatory diseases and gastrointestinal disorders (like Crohn's disease), gout and multiple sclerosis. Katexco has taken exclusive licenses from Stanford University on key technology necessary for the development of its proprietary pharmaceutical.

"Many pharmaceutical companies have identified small molecular weight and orally bioavailable agonists of cannabis which were tested in preclinical experiments and will now enter human trials in 2019," said Rothbard. "There will be an expansion of possible indications, not just for pain and inflammation but also extending from gastrointestinal to cardiac indications. Patients and consumers will start looking for quality and quantifiable dosage which will be provided by pharmaceutical companies rather than the current nutraceutical companies that are getting product from anywhere and prescribed loosely."

Dr. Steinman also served on the Board of Directors of Centocor, which was sold to Johnson & Johnson (JNJ) for $4.9 billion in 1998. He also founded Neurocrine Biosciences NBIX in 1992 and served on its Board of Directors.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any securities mentioned.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider several names mentioned to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

TAGS: Investing | Small Cap | Biotechnology | Cannabis

More from Cannabis

KushCo Sprinkles Some Gems on Its Earnings Call

Debra Borchardt
Jan 17, 2021 8:15 AM EST

The cannabis packaging company is looking at Arizona and New Jersey as new markets for growth.

I'm Coming Back Around to LiDAR Related Names

Timothy Collins
Jan 13, 2021 1:01 PM EST

Three stocks top my list for plays: Velodyne Lidar, Luminar Technologies, and Collective Growth Crop.

Jushi Holdings Puts Growth Plans in High Gear

Debra Borchardt
Jan 13, 2021 10:00 AM EST

The cannabis cultivator and retailer plans to nearly double its number of dispensaries in 2021.

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

Debra Borchardt
Jan 11, 2021 4:30 PM EST

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.

Democrat Wins Means Cannabis Wins

Debra Borchardt
Jan 9, 2021 8:15 AM EST

Georgia's election results have given the industry a big green light, meaning positive moves are expected out of cannabis stocks.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login